Rezo is pursuing an integrated approach to drug discovery that leverages the multiple technologies and tools needed to bring disease networks into focus, pinpointing novel targets and therapies with more clarity. Rezo’s Sequence to Systems to Drugs (SSD) platform integrates proteomics, genetics, structural biology, chemistry and bioinformatics to create maps of molecular disease networks. Based on the work of the founding team at the Quantitative Biosciences Institute (QBI) at the University of California, San Francisco (UCSF), the company’s mission is to break the mold in traditional drug development, which is slow and often siloed. The company’s initial focus is in oncology, with plans to explore additional therapeutic areas through collaborations and partnerships.

Rezo Therapeutics

Rezo Therapeutics